Nephron Pharmaceuticals’ Post

📢 Big News from Hyloris Pharmaceuticals! 🌟 Hyloris Pharmaceuticals, a pioneering specialty biopharma company dedicated to reimagining existing medications, proudly announces the U.S. FDA Approval of Maxigesic® IV. 👉 Maxigesic® IV, a powerful non-opioid pain reliever, will be marketed in the U.S. as Combogesic® IV. This approval marks a significant milestone, with first U.S. sales expected in early 2024, triggering a substantial milestone payment of USD 2.1 million. stijn van rompay, CEO of Hyloris Pharmaceuticals, shared his pride in the team's accomplishments, highlighting their role in addressing the opioid crisis in the largest healthcare market globally. Maxigesic® IV exemplifies Hyloris' strategy of bringing innovative products to market efficiently, with a development timeline of 7 years or less and R&D costs averaging less than EUR 7 million. This remarkable achievement reflects the collaboration between Hyloris Pharmaceuticals, AFT Pharmaceuticals, and Hikma Pharmaceuticals, aiming to revolutionize post-operative pain management in the U.S. In the wake of the opioid pandemic, Maxigesic® IV is poised to make a difference, offering a non-opioid alternative to patients and contributing to the reduction of opioid-related complications. Read the full press release: https://lnkd.in/exMiFHd5 #HylorisPharmaceuticals #MaxigesicIV #FDAApproval #Innovation #MedicalBreakthrough

The cataract pharmaceutical market in the United States and Western Europe, estimated by Market Scope to be worth $1.8 billion in 2023, is quite competitive. Only three companies have double-digit shares of the market: Bausch + Lomb, AbbVie, and Novartis. The next closest competitors are Rayner, Ocular Therapeutix, Inc., and Alcon. A single branded product, even with small unit share, can vault a company into a leading position in the market—as Omidria does for Rayner. Manufacturers compete for drug sales to ophthalmic surgeons, ASCs, and hospitals with three types of products: proprietary, patent-protected products; generic products; and compounded products. Some manufacturers (such as Bausch + Lomb) offer both patented products and generic products, while some (such as Alcon) offer only patented products and others (such as Altaire Pharmaceuticals Inc and 2care4 Group) specialize in generic products. Then there are large compounding pharmacies. Compounding pharmacies use the same active pharmaceutical ingredients as pharmaceutical manufacturers but are not regulated in the same way, because they supposedly are not mass-producing drugs without prescriptions. The development of logistics as a profession and of just-in-time supply and automated inventory systems in the late 20th century, however, made it possible to collect and fill identical prescriptions en masse and deliver them when and where they are needed. ImprimisRx® - A Harrow Company, Ocular Science®, and Edge Pharma, LLC are examples of compounding pharmacies in the United States that use such technologies. Specialist Pharmacy and Roseway Labs are leading compounding pharmacies in the UK. The “2023 US and Western Europe Cataract Pharmaceuticals Market Report” offers an in-depth examination of the cataract pharmaceuticals market in these regions, forecasts market performance over the next five years, and analyzes the competitive landscape. The report analyzes products currently on the market and examines the development pipeline, discusses the popularity of intracameral injections and fixed combination eye drops, and analyzes the roles of brand name medications, generics, and compounded formulations. For more information or to request a sample, please visit https://bit.ly/23CatPharma or email [email protected]. #Ophthalmology #CataractSurgery #Cataract #Pharmaceuticals #Market #MarketGrowth #CompetitiveLandscape #Patented #Generic #Compounded

Endo introduces generic Thiola EC tablets

NRx Pharmaceuticals today announced the signing of a development contract to manufacture a presentation of ketamine suitable for intravenous administration under current FDA manufacturing regulations. -FDA-compliant manufacture of intravenous Ketamine is a required component of a New Drug Application -Intravenous Ketamine has become widely used for treating depression and suicidality but has never been presented to FDA for approval -Potential to file New Drug Application for Ketamine in 2024 based on existing clinical data and newly-developed, modern commercial manufacturing protocols -Further information is anticipated to be released in an upcoming 8K securities filing Read More - https://lnkd.in/dSznyd5A #mentalillness #mentalhealth #mentalhealthawareness #mentalhealthmatters #suicidality #depression #ketamine

EyePoint Pharmaceuticals Highlights the P-II Results for EYP-1901 to Treat Wet Age-Related Macular Degeneration #eyepointpharmaceuticals #eyp1901 #wetagerelatedmaculardegeneration #clinicaltrial #phase2 #davio2 #ophthalmology #eyecare #eyetreatment #antivegfinjections #primaryendpoint #secondaryendpoint

https://lnkd.in/d9wsTEhU Marlex Pharmaceuticals, Inc. has initiated a voluntary recall of a single lot of Digoxin Tablets USP, 0.125mg, and another lot of Digoxin Tablets USP, 0.25mg, at the consumer level due to a labeling mix-up. Visit MedicoInsights to read the full news #HealthcareNews #drugs #StayInformed #MedicalNews #pharmanews #HealthTrends #Insights #HealthIndustry #HealthInnovation #BioProtect #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights

The global Intravitreal IVT Injectables market was valued at US$ 14530 million in 2023 and is anticipated to reach US$ 22480 million by 2030 witnessing a CAGR of 6.3% during the forecast period 20242030. Global top five manufacturers hold a share over 70%. North Amercia is the largest market with a share over 50% followed by Europe and AsiaPacific both have a share over 40 percent. In terms of drug AntiVEGF is the largest segment with a share over 85%. #GlobalIVTMarket #IntravitrealInjectables #EyeHealth #Pharmaceuticals #HealthcareIndustry #MarketGrowth #AntiVEGF #Corticosteroids #Pharmacies #MarketOutlook

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has reported its seventh consecutive rise in revenues to a quarterly record due to strong growth in its Enerzair and Atectura #asthma therapies. The Canadian pharmaceutical company posted a 132% increase in revenue to $14.1 million for the third quarter of its financial year, with #Enerzair and #Acetura up 234%. Adjusted gross profit more than doubled to $5.1 million from a year earlier. The company noted that Enerzair and Atectura prescribing physicians reached 2,503 at the end of July, showing 23% growth for the quarter and 221% increase year-over-year. Prescriptions for the two therapies rose 163% from a year earlier to a total of 18,384, taking the total subscriptions for the previous 12 months to 56,021. More at #Proactive #ProactiveInvestors #TSX #OTCQB #VPH #VPHIF #ValeoPharma http://ow.ly/P42U104Ug8h

The Top 10 Secondary Pharmaceutical Wholesalers. In the ever-evolving pharmaceutical landscape, independent pharmacies play a crucial role in providing personalized care to their communities. Choosing the right secondary pharmaceutical wholesaler is pivotal for their success. This article delves into the top 10 secondary pharmaceutical wholesalers tailored for independent pharmacies, highlighting essential considerations. Anda Capital Wholesale Drug Company (Capital Drug) Republic Pharmaceuticals Independent Pharmacy Cooperative (IPC) PARMED Trxade TopRx KeySource Smith Drug Company Masters Pharmaceutical https://lnkd.in/dsZuKdUV

Quoin Pharmaceuticals Provides Corporate Update - https://lnkd.in/gKC7ftka Follow #citybiz on LinkedIn - https://lnkd.in/eBgXKiz8 Quoin Pharmaceuticals #pharmaceuticalmanufacturing #corporateupdate